An interventional study of high-dose calcium (400 mg x 4), vitamin D (19 mikg x 4), and active vitamin D supplementation (2 mikg x 2) and Ommit routine blood test post operative day 1 in Hypoparathyroidism Post-surgical and Quality of Life, sponsored by Aarhus University Hospital. Enrolling by invitation at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by Aarhus University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Hypoparathyroidism with a site in Denmark — 3 open to participants now, 6 under way, 2 of them phase 3. Hypoparathyroidism · Denmark.
Among the 21 studies in Hypoparathyroidism with a site in Denmark, this one is the 4th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 5 with no phase, and was the 21st registered.
128 studies on the registry are indexed under Hypoparathyroidism; 30 are open to participants now.
Browse Hypoparathyroidism studies →3 of the 21 studies in Hypoparathyroidism with a site in Denmark are open now. Recruiting first, the newest first:
Lars Rejnmark · Sites in Denmark
Ages 18+
Aarhus University Hospital · Sites in Denmark
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 26 Hypoparathyroidism studies recruiting now, 19 (73%) set no upper age limit and 5 (19%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 50 across 77 interventional studies indexed under Hypoparathyroidism.
Median enrollment 78 across the 15 interventional studies, 100 across the 6 observational. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 21 have an industry lead sponsor. The 10 most frequent:
Aarhus University Hospital is the lead sponsor of 298 studies on the registry; 80 are open to participants now.
Aarhus University Hospital has 2 studies filed under Hypoparathyroidism — fewer than ten, so there is no comparison to draw.
2 of the studies in Hypoparathyroidism with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06222606Aarhus University HospitalSurgery for Thyroid Cancer With or Without Autofluorescence to Prevent Hypoparathyroidism | 2027-01 |
| NCT07381998Aarhus University HospitalEffects of Total Thyroid Removal on Parathyroid Function and Quality of Life | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 21 studies in Hypoparathyroidism with a site in Denmark, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Postoperative hypoparathyroidism (hypoPT) is the most frequent complication after total thyroidectomy (TT). It is caused by impaired parathyroid function, leading to low calcium levels, patient discomfort, reduced quality of life (QoL), and increased healthcare costs. Traditionally, all TT patients undergo routine postoperative blood testing and standard calcium supplementation, despite varying individual risk.
This investigator-initiated project aims to improve patient outcomes by using intraoperative parathyroid hormone (ioPTH) measurements to guide postoperative care. The ioPTH decline reflect parathyroid function immediately after surgery and can identify patients at high or low risk of hypoPT.
The study is designed as a prospective, randomized controlled trial (RCT) with two arms:
Arm A (\<75% ioPTH decrease): Patients randomized to either omission of routine postoperative calcium/PTH blood tests or standard monitoring.
Arm B (>75% ioPTH decrease): Patients randomized to either early high-dose calcium and vitamin D supplementation or standard therapy.
Primary outcomes are calcium and PTH levels postoperatively, incidence of hypocalcemia, and healthcare resource use. Secondary outcomes include QoL assessed by validated questionnaires (ThyPro39, SF-36, HPQ27), transient and permanent hypoPT rates, and other surgical complications.
By tailoring care to individual risk, the study aims to safely reduce unnecessary blood tests and optimize early treatment for high-risk patients. This approach has the potential to shorten hospital stays, reduce symptoms, improve QoL, and lower costs. The findings may influence clinical guidelines nationally and internationally, supporting more personalized and evidence-based management of TT patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard blood test on post operative day 1 including PTH and P-ca
Ommit routine blood test on post operative day 1
Diagnostic Test: Ommit routine blood test post operative day 1
Standard treatment
Start in Unikalk 4 times per day + d-vitamin + alfacalcidol 2 microgram 2 times per day.
Drug: high-dose calcium (400 mg x 4), vitamin D (19 mikg x 4), and active vitamin D supplementation (2 mikg x 2)
Standard postoperative treatment includes low-dose calcium (400 mg x 2) and vitamin D (19 mikg x 2) is initiated for all patients. In the intervention group, patients are randomized to standard low-dose (control group) or standard high-dose treatment including immediate postoperative initiation of high-dose calcium (400 mg x 4), vitamin D (19 mikg x 4), and active vitamin D supplementation (2 mikg x 2). In the control group, treatment with active vitamin D is only initiated in case of low PTH (\<1.0 pmol/L) and low Ca2+ (\<1.10 mmol/L).
Patients are randomized to either clinical monitoring only, without routine postoperative POD1 measurements of Ca2+ and PTH in one group or standard postoperative care, including routine blood tests for Ca2+ and PTH at POD1. All patients will have Ca2+ and PTH measured after the first postoperative week
Plasma ionized calcium (Ca2+) concentration at postoperative week 1 (POD7), by POD1 biochemical testing status
Comparison of plasma ionized calcium (Ca2+ mmol/L) and parathyroid hormone (PTH pmol/L) after one postoperative week between patients with and without biochemical measurements at post operative day 1 (POD1.)
Time frame: 2 years
Plasma ionized calcium (Ca2+ mmol/L) concentration on postoperative day 2 (POD2)
Comparison of plasma ionized calcium (Ca2+ mmol/L) between groups at postoperative day 2 (POD2).
Time frame: 1 year
Incidence of clinically significant hypocalcemia requiring medical intervention through 12 months
Proportion of participants with clinically significant hypocalcemia, defined as plasma ionized calcium (Ca2+) \< 1.10 mmol/L and/or presence of symptoms of hypocalcemia, necessitating medical intervention (e.g., IV calcium and/or initiation or escalation of oral calcium ± vitamin D). Incidence will be compared between arms.
Time frame: 2 years
Number of postoperative blood tests through 12 months
Total number of postoperative blood tests per participant (count), compared between arms.
Time frame: 2 years
Length of index hospital stay after surgery
Duration of initial postoperative hospital stay per participant, measured in days (or hours), compared between arms.
Time frame: 2 years
Change from baseline in Thyroid-Specific Patient-Reported Outcome measure (ThyPRO-39) score through 12 months
Change from baseline in Thyroid-Specific Patient-Reported Outcome measure (ThyPRO-39) score assessed at baseline and at 1 week, 2 months, 6 months, and 12 months. Scores are transformed to a 0-100 scale (minimum 0, maximum 100); higher scores indicate worse thyroid-related quality of life (more symptoms/impairment).
Time frame: 2 years
Change from baseline in 36-Item Short Form Health Survey (SF-36) score through 12 months
Change from baseline in 36-Item Short Form Health Survey (SF-36) domain scores assessed at baseline and at 1 week, 2 months, 6 months, and 12 months. Each domain score ranges from 0 to 100 (minimum 0, maximum 100); higher scores indicate better health status/quality of life.
Time frame: 2 years
Change from baseline in Hypoparathyroidism Patient Questionnaire (HPQ-27/HPQ-28) score through 12 months
Change from baseline in Hypoparathyroidism Patient Questionnaire (HPQ-27/HPQ-28) score assessed at baseline and at 1 week, 2 months, 6 months, and 12 months. Scores are transformed to a 0-100 scale (minimum 0, maximum 100); higher scores indicate worse disease control / greater symptom burden
Time frame: 2 years
Adverse events frequency through 12 months
Number and proportion of participants experiencing any adverse event, compared between arms.
Time frame: 2 years
Incidence of transient hypoparathyroidism through 12 months
Proportion of participants with transient hypoparathyroidism, defined as plasma ionized calcium (Ca2+) \< 1.10 mmol/L and/or need for treatment with alfacalcidol, with subsequent resolution (i.e., no longer meeting the definition and not requiring alfacalcidol) within 12 months. Incidence will be compared between arms.
Time frame: 2 years
Incidence of permanent hypoparathyroidism at 12 months
Proportion of participants meeting the hypoparathyroidism definition (plasma ionized calcium (Ca2+) \< 1.10 mmol/L and/or need for alfacalcidol) that persists at 12 months, with continued need for alfacalcidol beyond 12 months. Incidence will be compared between arms.
Time frame: 2 years
Incidence of postoperative bleeding complication through 30 days
Proportion of participants with postoperative bleeding/hematoma requiring intervention (e.g., re-operation), compared between arms.
Time frame: 2 years
Incidence of postoperative infection through 30 days
Proportion of participants with postoperative infection requiring antibiotics and/or drainage, compared between arms.
Time frame: 2 years
Incidence of nerve injury through 12 months
Proportion of participants with postoperative nerve injury, defined as recurrent laryngeal nerve palsy, assessed based on patient-reported voice function and confirmed by laryngoscopy, compared between arms.
Time frame: 2 years
Number of resected parathyroid glands
Number of resected parathyroid glands per participant (count) based on pathology report, compared between arms.
Time frame: 2 years
Number of lymph nodes removed
Number of lymph nodes removed per participant (count) based on pathology report, compared between arms.
Time frame: 2 years
Thyroid pathology findings
Final thyroid pathology diagnosis based on the postoperative histopathology report, categorized as cancer, goiter, or thyrotoxicosis-related pathology, and compared between arms
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Jul 2027, 18 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.